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Dominant mutations in the T-box transcription factor gene TBX5 cause Holt–Oram syndrome (HOS), an inherited human disease
characterized by upper limb malformations and congenital heart defects (CHDs) of variable severity. We hypothesize that minor alterations in
the dosage of Tbx5 directly influences severity of CHDs. Using a mouse allelic series, we show a sensitive inverse correlation between Tbx5
dosage and abnormal cardiac morphogenesis and gene expression. The CHDs found in mice harbouring a hypomorphic allele of Tbx5 (Tbx5lox/+
mice) are less pronounced than those found in Tbx5 haploinsufficient mice (Tbx5del/+), and homozygous hypomorphic (Tbx5lox/lox) embryos have
noticeably more advanced cardiac development than Tbx5 null (Tbx5del/del) embryos. Examination of target gene expression across the allelic series
uncovers very fine sensitivity across the range of Tbx5 dosages, in which some genes respond dramatically differently to only 15% differences in
Tbx5 mRNA levels. This analysis was expanded to a genome-wide level, which uncovered a Tbx5 dosage-sensitive genetic program involving a
network of cardiac transcription factors, developmentally important cell–cell signaling molecules, and ion channel proteins. These results indicate
an exquisite sensitivity of the developing heart to Tbx5 dosage and provide significant insight into the transcriptional and cellular mechanisms that
are disrupted in CHDs.
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Cardiogenesis requires the coordinated development of
many unique groups of cells that must precisely come together
to form the elements that make up the adult heart. Such
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state of heart development, as well as their location with respect
to other cells. Spatial and temporal information is ultimately
communicated to the nucleus of developing heart cells by
activation of specific sets of cardiac transcription factors
(reviewed by Bruneau, 2002; Moorman et al., 2004; Mori and
Bruneau, 2004; Srivastava and Olson, 2000).
Changes in the functional concentration of cardiac
transcription factor proteins, due to dominant mutations in
one allele (haploinsufficiency), can result in congenital heart
defects (CHDs) in humans (Bruneau, 2002; Epstein and
567A.D. Mori et al. / Developmental Biology 297 (2006) 566–586Buck, 2000; Gruber and Epstein, 2004). The CHDs associated
with DiGeorge Syndrome (OMIM #188400) and Holt–Oram
syndrome (OMIM #142900) are caused by dominant muta-
tions in the T-box transcription factor genes TBX1 (Jerome
and Papaioannou, 2001; Lindsay et al., 2001; Merscher et al.,
2001; Yagi et al., 2003) and TBX5 (Basson et al., 1997; Li et
al., 1997; Mori and Bruneau, 2004), respectively. In addition,
non-syndromic CHDs have been reported in families with
dominant mutations in the homeobox transcription factor gene
NKX2-5 (Benson et al., 1999; Schott et al., 1998) and zinc-
finger transcription factor gene GATA4 (Garg et al., 2003;
Okubo et al., 2004).
Work conducted to date examining the mechanistic basis
behind Holt–Oram syndrome (HOS) has focused on describing
the genetic and phenotypic changes resulting from Tbx5
haploinsufficiency (Basson et al., 1997; Bruneau et al., 2001;
Li et al., 1997; Mori and Bruneau, 2004, and references therein).
However, examination of phenotype is complicated by large
variations in CHD severity of HOS clinical presentation, even
between members of the same family. Attempts to correlate
mutations in TBX5 with severity of HOS manifestation have
yielded mixed results but generally suggest that genetic
modifiers influence CHD severity more than environmental or
genotypic differences (Basson et al., 1999; Brassington et al.,
2003; Huang et al., 2002).
Cis-regulatory modules frequently contain multiple sites for
a single transcription factor (Davidson, 2002; Markstein et al.,
2004) and required occupancy of multiple independent DNA-
binding interactions would confer increased dosage sensitivity
(Seidman and Seidman, 2002). Indeed, Nppa and Gja5, genes
sensitive to Tbx5 dosage in mouse, have several Tbx binding
sites in their regulatory regions (Bruneau et al., 2001, and
unpublished data). We hypothesized that subtle alterations in
Tbx5 dosage due to underlying genetic and/or environmental
conditions may account for the variation in HOS manifestation
and by extension that genes most sensitive to dosage would be
altered in all HOS patients, whereas others would only show
changes in a subset of severe cases. Understanding which genes
are most sensitive to Tbx5 dosage and therefore most likely
altered in the diseased state would be an important step in
understanding and treating CHDs caused by transcription factor
haploinsufficiency.
Tbx5 heterozygous null (Tbx5del/+) mice recapitulate the
CHDs seen in HOS patients whereas homozygous null mice
(Tbx5del/del) are growth arrested at E9.0 and die in utero by
E10.5 due to severe heart defects (Bruneau et al., 2001). Here
we show that the conditional allele (Tbx5lox)–which was a
precursor to the Cre-induced null allele–is hypomorphic, thus
creating an allelic series based on dosage of Tbx5. Hypomorphic
mutants exhibit milder defects than the respective null mutants,
both in the heterozygous state as models of HOS, and as
homozygous embryos with defective cardiac morphogenesis.
Furthermore, we show that increases in CHD severity are linked
to differential changes in expression of downstream targets of
Tbx5. By gene expression profiling, we identify genes with
variable sensitivity to Tbx5 dosage and determine that Tbx5 is
likely to regulate complex transcriptional networks. Theexquisite sensitivity of downstream genes to Tbx5 dosage
provides a mechanistic explanation for the large differences in
HOS clinical presentation; the identified targets provide an
entry point to understanding the complex phenotypes caused by
Tbx5 haploinsufficiency.Materials and methods
Animals
Tbx5lox/+ and Tbx5del/+ mice were generated and genotyped as previously
described (Bruneau et al., 2001). For removal of the Neor gene, Tbx5lox/+ mice
were bred to EIIaCre mice (129SvJ strain; Jackson Laboratories, Bar Harbour,
ME) and genotyped for the presence of Tbx5 exon 3 and the absence of Neor
using PCR. The EIIaCre was removed from the germ-line by breeding into
129SvEv and genotyping for the absence of Cre. This new mouse strain
Tbx5LDN/+ was bred 4 generations into 129SvEv before homozygous mice
were generated. All methods performed on animals used in this study were
approved by the Animal Care Committee of the Hospital for Sick Children.
In vivo electrocardiogram (ECG) telemetry collection
Twelve-week-old adult mice were anesthetized and EA-F20 telemetry
device (Data Sciences International; St. Paul, MN) were implanted dorsally with
electrodes in a lead II configuration. Mice were allowed to recover for 60h post-
surgery before ECG data were collected. Twenty measurements per ECG trace
were collected during nocturnal activity (between 0:00 and 7:00) over at least
two consecutive days. Data points were averaged to give a single value per
mouse per parameter value examined. P wave width, P wave amplitude, PQ
interval duration, QRS interval duration, QRS wave amplitude, ST interval
duration, and heart rate were measured.
Magnetic resonance imaging (MRI) and optical projection
tomography (OPT)
Mice were fixed for whole-body MRI by ultrasound guided left-ventricular
catheterization as previously described (Zhou et al., 2004). MR images were
subsequently obtained with a 40-cm bore, 7-T magnet (Magnex Scientific,
Oxford, UK) operated by a UnityINOVA console (Varian NMR Instruments,
Palo Alto, CA). We used a conventional three-dimensional spin-echo sequence
with the following parameters: 300ms repetition time, 10ms echo time,
(28 × 28 × 120) mm3 field-of-view, and 420 × 420 × 1800 imaging matrix. Total
imaging time was 14.7h.
Optical projection tomography (OPT) was performed essentially, as
described (Sharpe et al., 2002), on embryos fluorescently labeled by in situ
hybridization against Actc and Mybpc3 (Lickert et al., 2004). Visualization and
manipulation of OPT data were performed with Amira 3.0 (Mercury Computer
Systems Inc. Chelmsford, MA).
In situ hybridization
Whole-mount in situ hybridization was preformed according to standard
protocols. Section in situ hybridization on paraffin sections was performed using
modifications of the whole-mount in situ hybridization protocol.
Microarray analysis
Total RNAwas isolated by TRIzol (Invitrogen, Carlsbad, CA) extraction from
14 to 20 pooled E11.5–E12.0 hearts and hybridized to Affymetrix MOE430A and
MOE430B chips according to manufacturer's protocol. To reduce strain variations,
the mice used for this experiment were kept in the same genetic background (50%
129SvEv, 50% Black Swiss). Three chip sets were run for RNA isolated from
wild-type hearts, 3 for Tbx5lox/+ and 4 for Tbx5del/+. Statistical comparisons of
chip data were performed using GC-Robust Multichip Analysis (ArrayAssist
V2.6.1642.30743; Iobion Informatics, Toronto, CA.) (Irizarry et al., 2003; Wu
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against wild-type chips. A probe-set expression was considered altered if it
had a P < 0.05 vs. wild type (unless stated otherwise). Hierarchical clustering
was performed using SpotFire DecisionMaker software (Somerville, MA).
Quantitative real-time PCR
Total RNA was isolated from either whole embryos (E8.5) or isolated
cardiac tissue (E12.5) using TRIzol reagent. Quantitative real-time PCR was
performed using TaqMan probe sets (Applied Biosystems). Expression data
were analyzed using the ΔΔCT method (Livak and Schmittgen, 2001).
GAPDH was chosen as a control gene. The network represented in Fig. 9 was
created using Biotapestry (Ver. 0.96.0) available at http://labs.systemsbiology.
net/bolouri/software/BioTapestry/.
MULAN multispecies alignment
The mouse DNA sequence 25kb upstream and 15kb downstream (or until
the start of the adjacent gene) of genes identified on microarray and confirmed
altered in Tbx5del/+ mutants using either quantitative real-time PCR or in situ
hybridization were entered into the multisequence local alignment tool MULANFig. 1. The Tbx5 allelic series (A) Tbx5 alleles from the top to the bottom: Tbx5lox, Tb
encoding sequences and triangles are loxP sites. (B) Expression of aberrant transcr
amplify Tbx5exon2–Neor hybrid mRNA detect two alternatively spliced transcripts fr
mRNA (top bands). mRNA containing Tbx5 exon 3 is amplified from mRNA fromW
analysis of Tbx5-exon 3 expression from either whole embryo lysate at E8.5 or isolat
(D) Quantitative real-time PCR examining activity at the Tbx5 locus by examining ex
increased activity from the Tbx5del allele. *P < 0.05 versus WT.(http://mulan.dcode.org; Ovcharenko et al., 2005) along with the homologous
sequences from the rat, dog, and human genomes (where available) to identify
evolutionarily conserved domains likely to contain conserved transcription
factor binding sites. Once the genomic regions were aligned, multi-TF
transcription factor binding site analysis was performed using a predefined
matrix similarity of 0.85 to the PWMs shown in Fig. 8A. Two adjacent Tbx5
sites or a Tbx5 site adjacent to an Nkx2.5 site separated by less than 500bp was
considered to be clustered. A Tbx5-insensitive gene is defined as a gene altered
only in Tbx5del/del or Tbx5lox/lox mutants. A Tbx5-independent gene is defined as
a gene known not to be altered in any Tbx5 mutant.Results
Identification of a Tbx5 hypomorphic allele
Previous work has shown that aberrant splicing into a
neomycin resistance cassette (Neor) contained within the
coding region of an active gene can result in the reduction or
complete inactivation of gene expression (Meyers et al., 1998;x5LDN, Tbx5del; exons are indicated by roman numerals, open boxes show T-box
ipts from the Tbx5lox allele detected by RT-PCR at E10.5. Primers designed to
om Tbx5lox/lox mRNA, which are absent from wild-type (WT) and Tbx5LDN/LDN
T, Tbx5lox/lox, and Tbx5LDN/LDN (bottom bands). (C) Quantitative real-time PCR
ed hearts at E12.5. Each mutant is normalized to its respective wild-type control.
pression of Tbx5-exon 1 containing mRNA isolated from E12.5 hearts showing
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used for embryonic stem cell selection (Bruneau et al., 2001).
We hypothesized that Tbx5lox might be a hypomorphic allele.
Indeed, we could not recover live born Tbx5lox/lox mice from
crosses of Tbx5lox/+ animals (see below). To test whether
aberrant splicing was occurring in transcripts made from the
Tbx5lox allele, primers were designed in exon 1 and the 3′ end of
Neor (Supplemental Figure 1), and potential hybrid mRNAs
containing both Neor and Tbx5 sequences were amplified using
reverse transcriptase-polymerase chain reaction (RT-PCR) (Fig.
1B). Two aberrantly spliced transcripts were seen in Tbx5lox/lox
samples, in addition to normal Tbx5 mRNA. Sequencing of
these products confirmed erroneous splicing of normal Tbx5
transcript after exon 2 into the Neor cassette. Both aberrant
amplicons introduce stop codons into the primary Tbx5
transcript shortly after splicing into Neor and would lack
sequence encoding the T-box DNA binding motif of Tbx5; they
are therefore presumed inactive. Alternative transcripts are
absent in the wild-type control.
Selective removal of the Neor cassette created the new allele
Tbx5LDN, which retains functional loxP sites flanking Tbx5 exon
3 (Fig. 1A). RT-PCR from Tbx5LDN/LDN RNA extracted at E10.5
shows only Tbx5 mRNA with no alternatively spliced mRNA
and thus is analogous to wild type (Fig. 1B). Tbx5LDN/LDN mice
are viable and live for more than one year.
Allelic series created by conditional allele of Tbx5
Both Tbx5lox and Tbx5del alleles express mRNA containing
Tbx5 exons 1 and 2 but not exon 3. To quantitate levels of
wild-type Tbx5 mRNA production in mutant backgrounds,
primers were designed across the exons 2–3 boundary to
specifically amplify functional exon 3-containing Tbx5 mRNA
(Supplemental Figure 1). Quantitative real-time (qRT)-PCR
was performed on RNA isolated from E8.5 embryos at the
linear heart tube stage (before homozygous mutants die) and
on RNA isolated from E12.5 hearts at the stage prior to cardiac
septation in heterozygous mutants (Fig. 1C). The average
amount of functional Tbx5 transcripts in Tbx5lox/+ mice is
similar at E8.5 (78 ± 1% of WT) and E12.5 (67 ± 10% of WT)
(P = N.S.). In contrast, Tbx5del/+ embryos express 30 ± 3%
wild-type Tbx5 levels at E8.5 (P < 0.005 vs. WT), and
expression increases to 55 ± 11% by E12.5 (P < 0.06 vs. E12.5
Tbx5lox/+; P < 0.005 vs. WT). Tbx5lox/lox embryos at E8.5 have
22 ± 1% functional Tbx5, suggesting that splicing variants
account for approximately 80% of all transcripts from the
Tbx5lox locus. No exon 3-containing Tbx5 transcripts were
detected from any of the Tbx5del/del embryos examined (n = 8).
Reduced expression from the Tbx5lox allele creates an allelic
series based on decreasing dosage of Tbx5 (from highest
Tbx5 expression to lowest: Tbx5+/+ > Tbx5lox/+ > Tbx5del/+ >
Tbx5lox/lox > Tbx5lox/del > Tbx5del/del).
To confirm that the observed decreases in Tbx5 expression
were due to changes in the level of functional mRNA and not
merely inactivity at the Tbx5 locus, qRT-PCR was performed
using primers designed to amplify Tbx5 exon 1-containing
mRNA (expressed from both endogenous and mutant Tbx5alleles (see Supplemental Figure 1) to measure total activity
from the Tbx5 locus at E12.5 (Fig. 1D). Similar activity levels
were observed between Tbx5lox/+ embryos and the two wild-
type strains. Unexpectedly, however, Tbx5del/+ embryos
showed a statistically significant increase in Tbx5 exon 1-
containing mRNA over its strain-matched wild-type control
(183 ± 58% vs. 100 ± 37%; P < 0.005). As this increased
activity was not accompanied by increased Tbx5 exon 3
mRNA, we conclude that transcriptional activity was only
increased from the null allele, which could suggest that the
creation of the Cre-induced null allele removes a negative
regulatory element and leads to a selective increase in this
allelic variant of Tbx5.
Congenital heart defects in Tbx5 hypomorphic heterozygous
mice
Crosses of Tbx5lox/+ (129SvEv background) and wild-
type 129SvEv mice yielded 42% Tbx5lox/+ pups (76 of 180
examined; P < 0.05) at weaning suggesting that approxi-
mately 27% of Tbx5lox/+ mice died prior to weaning. This
phenotype is considerably milder than that seen in Tbx5del/+
mice, which show greater than 90% perinatal death in a
129SvEv background (Bruneau et al., 2001), and 59%
perinatal death in a Black Swiss outbred background (36
Tbx5del/+ pups of 124 mice alive at weaning (P < 0.001
altered from the 50:50 expected ratio). In comparison,
Tbx5LDN/+ mice survived to weaning in Mendelian propor-
tions (65 Tbx5LDN/+ mice of 122 examined at weaning;
P = N.S.) and lived for more than 1year afterwards.
Cardiac defects in surviving Tbx5lox/+ mice were assessed at
12weeks of age by closed-chest magnetic resonance imaging
(Figs. 2A–C). Atrial septal defects (ASDs) were found in all
Tbx5del/+ and Tbx5lox/+ mice examined and all showed an
enlargement of the atria consistent with the interatrial commu-
nications. Quantitation of ASD size indicated smaller ASDs in
Tbx5lox/+ mice compared to Tbx5del/+ mice (Table 1). Wild-type
and Tbx5LDN/LDN mice show no ASDs or cardiac dilation of any
sort. No ventricular septal defects (VSDs) were observed in live
heterozygous hypomorphic or null mutants.
Conduction system function of WT, Tbx5lox/+, Tbx5del/+,
and Tbx5LDN/+ mice at 12weeks of age was examined using
ECG telemetry over a 2-day period. A statistically significant
increase in PQ-interval duration was measured in Tbx5lox/+
hearts with respect to 129SvEv wild-type mice (37.1 ± 2.5ms,
n = 5 vs. 32.6 ± 0.7, n = 4, respectively; P < 0.01), indicative
of first degree atrioventricular (AV) block (Table 1). This
block is significantly less severe than that seen in Tbx5del/+
mice (40.1 ± 1.3ms, P < 0.05 vs. Tbx5lox/+; P < 0.0002 vs.
wild type). No other significant differences were observed for
any other measurements. In addition, continuous monitoring
of Tbx5lox/+ mice over 48h showed sporadic electrophysio-
logical anomalies, including occurrences of ventricular
tachycardia, sinus rhythm with premature atrial complexes,
secondary degree AV block and sinoatrial (SA) pauses (Figs.
2D–G) similar to those previously reported in Tbx5del/+ mice
(Bruneau et al., 2001).
Fig. 2. Physical and physiological characterization of adult Tbx5lox/+ and Tbx5del/+ hearts (A–C) Closed-chested in vivo MRI images of 12-week-old mouse hearts.
Representative MRI of aWTor Tbx5LDN/LDN heart (A) shows the normal septal divisions expected in the adult heart. Hearts of Tbx5lox/+ (B) mice show small interatrial
communications (red arrows) similar to those seen in Tbx5del/+ mice (C). The changes in hemodynamics caused by these ASDs leads to dilatation of the atrial wall
(green arrows). (D–G) Sporadic electrophysiological anomalies detected in Tbx5lox/+ mice over continuous 24h recordings include occurrences of ventricular
tachycardia (D), sinus rhythm with atrial complexes (E), second degree AV block (F), and sinoatrial (SA) pauses (G). Similar events were previously reported in
Tbx5del/+ mice (Bruneau et al., 2001).
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embryos
Tbx5lox/lox mice were growth arrested at E9.5 and died before
E11.5 (Fig. 3A). Tbx5lox/lox hearts at E8.5 had a hypoplastic left
ventricle (LV) and sinoatrial structures (primitive inflow track
and atria) whereas the right ventricle (RV) and outflow track
continued to develop, characteristic of Tbx5del/del heart
development at the same stage (Figs. 3B–D). Optical projectiontomography (OPT) imaging of E9.5 Tbx5lox/lox mutants
illustrated that heart development was arrested at E9.0 (Figs.
3E–M). Although Tbx5lox/lox hearts had begun to loop, both
atrial and ventricular structures were hypoplastic, lacking the
left/right distinctions that are normally apparent at this stage. By
comparison, E9.5 Tbx5del/del hearts had a single columnar
ventricle projecting from the chest cavity, previously demon-
strated to be outflow tract and RV (Bruneau et al., 2001),
whereas posterior structures (atria and LV) were severely
Table 1
Summary of congenital heart defect severity across the Tbx5 allelic series
+/+ lox/+ del/+ lox/lox del/del
Tbx5 dosage
Functional Tbx5 (exon 3)
E8.5 100 ± 47% (129 SvEv)
100 ± 10% (BS)
78 ± 1% 30 ± 3% 22 ± 1% 0 ± 0%
E12.5 100 ± 10% (129 SvEv)
100 ± 19% (BS)
68 ± 10% 55 ± 11% N/A N/A
Survival
To birth, 100%
survive at weaning
To birth, 129 SvEv:
73% alive at weaning
To birth, 129 SvEv:
10% alive at weaning BS:
40% alive at weaning
Death in
utero by E11.5
Death in utero
by E10.5
Cardiac structure
12weeks post-natal Normal ASD (100% of hearts) ASD (100% of hearts) N/A N/A
ASD size (voxel dimensions
standardized to spinal
cord width)
N/A 93 ± 109 280 ± 5 N/A N/A
E9.5 Normal Indistinguishable
from WT
Indistinguishable
from WT
Hypoplastic atria,
single ventricle
Severely hypoplastic
ventricles and atria
E10.5 Normal Indistinguishable
from WT
Indistinguishable
from WT
Bifurcated atrial tube,
single ventricle
N/A
Electrophysiological
PQ interval 32.59 ± 0.68ms
(129 SvEv)
2.45 ± 1.18ms (BS)
37.09 ± 2.49ms 40.10 ± 1.32ms N/A N/A
Sporadic electrophysiological
anomalies (3rd degree
AV block, SA pauses,
tachycardia, etc.)
Rare: 0–3 events per
24-h period
Common: up to 10
events per hour
Common: up to
10 events per hour
N/A N/A
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the four chambers of the wild-type heart were evident, and the
atrial septum and cardiac cushions were beginning to form. In
contrast, Tbx5lox/lox hearts still had a tube-like atrium and single
ventricle. A groove had now appeared that bisects the tube-like
atrium (Fig. 3S). A separation between the two halves of this
atrial tube was evident (Fig. 3V) coincident with the initial
stages of separation of the common atrium into left and right
atria. No live Tbx5del/del mutants have ever been recovered at
E10.5, supporting our observations that Tbx5lox/lox embryos
have less severe defects in heart formation than Tbx5del/del
embryos.
Differential sensitivity of downstream genes to Tbx5 levels
Haploinsufficiency of Tbx5 results in dramatic changes in
gene expression. We have previously shown that expression of
Gja5 (encoding connexin 40) was reduced by 90% in hearts of
Tbx5del/+ mice, whereas expression of Nppa (encoding atrial
natriuretic factor) was also decreased, albeit less dramatically
(Bruneau et al., 2001). In Tbx5 null embryos, decreased Gata4,
Myl2, and Irx4 was observed (Bruneau et al., 2001). Expression
of these genes was assessed in our allelic series. It would be
expected that mice with lower levels of Tbx5 expression would
display a proportional reduction in cardiac differentiation
marker expression. However, changes in expression were not
uniform across all genes examined. Rather, we observe thatalthough the expression of some genes such as Irx4 (Fig. 3A)
and Gata4 (Fig. 4B) was significantly reduced in Tbx5lox/lox
embryos, expression of Myl2 (Figs. 3B–D) was unchanged
compared to wild-type littermates. Similarly, Nppa expression
was not altered in E9.5 Tbx5lox/+ embryos, whereas its
expression was reduced in Tbx5del/+ mice, as well as expanded
across the interventricular septum. Such differences are
manifest not only in changes throughout the entire heart but
also in changes in expression within certain tissue types: Gja5
expression was significantly reduced in the ventricles of
Tbx5lox/+ embryos at E9.5, whereas atrial expression of Gja5
was maintained closer to wild-type levels (Fig. 4C).
Gene expression profiling identifies Tbx5 dosage-sensitive
genes
The data presented above draw comparisons between distinct
populations of mice subdivided on the basis of genotype to show
a correlation between CHD severity and Tbx5 dosage. However,
subtle distinctions in phenotype are seen between individuals
within a given subgroup due in part to variable Tbx5 expression
in genetically identical mice (Fig. 5A). Along this continuum of
Tbx5 expression, it should be possible to differentiate genes that
are highly sensitive to minor perturbations in Tbx5 (whose
expression would be affected in both mild (Tbx5lox/+) and severe
(Tbxdel/+) HOS cases) from those that are not as sensitive (and are
therefore only affected in a subset of severe HOS cases). To this
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Fig. 4. Whole-mount in situ hybridizations showing gene expression changes for
known genes downstream of Tbx5. (A) a ventral view showing unchanged Nppa
expression in Tbx5lox/+ embryos at E9.5. Prominent Nppa expression is seen in
the LV of both wild-type and Tbx5lox/+ embryos and is absent from the
interventricular septum (red arrows). In contrast, Nppa expression is reduced in
the Tbx5del/+ embryos and is expanded across the interventricular septum. (B)
Ventral view of Gata4 expression at E8.5 showing decreased expression
throughout the cardiac crescent of Tbx5lox/lox and Tbx5del/del embryos. (C)
Lateral view of E9.5 embryos showing decreased expression of Gja5
specifically in the LV of Tbx5lox/+ mutants to a similar extent as in the
heterozygous null embryo. Atrial expression levels of Gja5 appear unchanged.
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from pooled E11.5–12.0 embryos (WT, Tbx5lox/+, and Tbx5del/+)
in order to assess the sensitivity of different genetic pathways to
varying dosages of Tbx5. To minimize strain-specific variation,
all embryos were of a mixed background (50% 129SvEv/50%
Black Swiss), and pools of 14–20 hearts further minimized
individual variation due to strain or minor staging differences.
Affymetrix MOE430A and MOE430B chips were used to
analyze the expression over 45,265 Unigene clusters (n = 3 WT
pools, 3 Tbx5lox/+ pools, and 4 Tbx5del/+ pools). After applyingFig. 3. Heart development in homozygous mutants. (A) Tbx5lox/lox embryos at E10.5
decreased in Tbx5lox/lox embryos at this stage. (B–D) Tbx5lox/lox embryos at E8.5 (C) h
and atria) whereas the right ventricle (RV) and outflow track continue to develop, cha
Tbx5lox/lox embryos (blue) whereas it is undetectable in Tbx5del/del embryos. (E–M) S
heart is red, embryo is translucent white. E9.5 Tbx5del/del embryo outflow tract growth
2001). By comparison, Tbx5lox/lox hearts havemore developed posterior cardiac struct
Virtual sections through hearts shown in panels E–G. (N–V)OPT images of E10.5Tbx
and single ventricle. A groove has appeared that bisects the tube-like atrium (white arro
Examination of the cavity below the groove seen in Fig. 3P shows a physical separatio
shown in panels N–P. Virtual section through the heart in panel S (plane parallel to the
single atria.GC-Robust Multichip Analysis (GC-RMA), we identified 177
genes as having significantly altered gene expression: 94 of these
genes are significantly altered in both Tbx5lox/+ and Tbx5del/+
mice (these genes represent highly sensitive Tbx5 gene targets,
likely to be affected in all HOS patients), whereas the other 83
showed changes only in Tbx5del/+ mice (these genes represent
moderately sensitive gene targets, likely altered in only a subset
of HOS patients). Of the initial 177 genes, only 98 showed strong
changes in expression (greater than log2 = ±0.3: defined as the
minimum threshold of expression needed for independent
validation by quantitative real-time PCR in our hands) (shown
in Fig. 5B). Among these 98 genes is Gja5, a direct target of
Tbx5 that is known to be affected by Tbx5 haploinsufficiency
(Bruneau et al., 2001). Furthermore, because changes in
expression of downstream targets are expected to be small, we
also looked at those hits with slightly higher P values
(0.05 < P < 0.10) to look for obvious cardiac genes potentially
falsely eliminated by the stringent GC-RMA screen. We noted
that the cardiac transcription factor genes Hand1, Irx2, and
Shox2, the putative Wnt antagonist gene Dkk3, and the signaling
molecule Slit2 were measured as having downregulated
expression (expression changes >log2 = ±0.3) in both Tbx5-
lox/+ and Tbx5del/+ mice just short of the P < 0.05 cutoff
(P = 0.0513, 0.0565, 0.0603, 0.0785, 0.0961, respectively, vs.
WT). Given that all five genes are expressed in the heart,
and may be involved in pathways related to Tbx5 function,
we included them as putatively downregulated pending
further experimentation, bringing the number of gene altered
in Tbx5del/+ hearts to 182 and the number of highly sensitive
genes to 99.
Classification of the 182 microarray genes into gene
ontology (GO) categories revealed predominant downregula-
tions of expression of transcriptional regulators (22%) and
signal transduction molecules (14%), whereas metabolic
genes were predominantly increased (18%) (Fig. 5C). By
comparison, classification by GO annotation across the entire
45,290 probe set database showed that transcriptional
regulation and signal transduction are only represented at a
rate of 5.8% and 4.4%, respectively. Whereas highly sensitive
Tbx5-regulated genes account for only 99 of 182 genes
altered in Tbx5del/+ mice, the relative ratios between
functional classes of genes affected were maintained,
suggesting that no single functional class of gene is more
sensitive to changes in Tbx5 dosage (Tables 2 and 3).
To independently confirm changes in expression of genes
identified above, we used whole-mount in situ hybridization at
E10.5 and section in situ hybridization at E11.5 to screen forare growth retarded compared to wild-type littermates. Irx4 expression (blue) is
ave hypoplastic left ventricle (LV) and sinoatrial structures (primitive inflow track
racteristic of Tbx5del/del heart development (D).Myl2 expression is maintained in
urface-rendered views of OPT on E9.5 WT, Tbx5del/del, and Tbx5lox/lox embryos;
continues whereas LVand atrial structures are almost non-existent (Bruneau et al.,
ures (H–J). Inner lumen of the hearts (yellow) are rendered in panels E–G. (K–M)
5lox/lox hearts compared towild type. Tbx5lox/lox hearts still have a tube-like atrium
ws in panel P). (Q–S) Inner lumen of hearts (yellow) are rendered in panels N–P.
n between the two halves of this atrial tube. (T–V) Virtual sections through hearts
green line) shows the development of a connection between the two halves of the
Fig. 5. (A) When individual Tbx5 expression levels from the E12.5 embryos used to generate Fig. 1C (diamond) are visualized, they make up a continuum of Tbx5
expression. Within this continuum, we see both mild CHDs (predominant in Tbx5lox/+ mice) and more severe CHDs (predominant in Tbx5del/+ mice). The average
expression is represented by the red box. (B) Cluster analysis of the 102 genes identified as being differentially expressed by microarray with expression changes
greater than log2 = ±0.3. Genes are clustered using a hierarchical clustering algorithm based in absolute expression changes verses wild type. (C) Pie charts examining
the distribution of functional classes (based on classification by gene ontology (GO) annotations) among the 99 highly Tbx5-dosage-sensitive genes, as well as among
the complete 182 gene set show predominant downregulations in transcriptional regulators (22%) and signal transduction (14%), whereas metabolic genes are
predominantly increased. Distribution of the 45K gene clusters on the MOE430 gene chips is also shown.
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(2610024A01Rik, Agpat3, Ddx52, Dkk3, Eya1, Fbx032,
Hand1, Hk1, Slit2, Tbx3, Vsnl1, Wisp1) in Tbx5del/+ mutants.
All 12 genes were expressed in the heart, and 8 of these
(2610024A01, Ddx52,Dkk3, Eya1, Fbx032,Hk1, Vsnl1,Wisp1)
were also expressed in the limbs. Obvious changes were seen
in the expression of 7 genes (Dkk3, Fbxo32, Hand1, Hk1, Slit2,
Tbx3, Wisp1), consistent with that seen on the microarray (Fig.
6). In addition, expansion of Wisp1 expression was noted
across the interventricular septum (Fig. 6F). Changes in theexpression of Agpat3 (Fig. 6A) and Ddx52 (data not shown)
were noted opposite to that reported by microarray. The
remainder of genes showed no appreciable change in expression
by in situ.
Gene expression kinetics
A more sensitive screen of the microarray data was
performed with qRT-PCR by examining the expression of 17
genes using RNA from individual E12.5 hearts; 12 genes
Table 2
Highly sensitive Tbx5 dose-dependant genes (altered in both Tbx5lox/+ and Tbx5del/+)
Up/downA Gene symbol Gene title Proposed biological functions Unigene code
Cell cycle
d Mcm2 Minichromosome maintenance-deficient
2 mitotin (S. cerevisiae)
Involved in DNA replication and cell
division
Mm.16711
Cellular/structural component
d a Lamp1 Lysosomal membrane glycoprotein 1 Lysosomal membrane glycoprotein;
unknown biological function
Mm.16716
D Mtdh Metadherin Nuclear membrane-associated protein;
unknown biological function
Mm.130883
Ua Mrps25 Mitochondrial ribosomal protein S25 Structural component of ribosome Mm.87062
U Pscd1 Pleckstrin homology, Sec7 and
coiled-coil domains 1
Membrane protein; unknown
biological function
Mm.86413
Channel-forming proteins
Da Cacna2d2 Calcium channel, voltage-dependent,
alpha 2/delta subunit 2
Sympathetic regulation of cardiac conduction Mm.100236
D b Cx40 Gap junction membrane channel
protein alpha 5
Gap junction protein involved in
cardiac conduction
Mm.281816
Db Kcna5 Potassium voltage-gated channel,
shaker-related subfamily, member 5
Potassium channel involved in
I(K,Slow1) current during cardiac conduction
Mm.222831
da Ttyh3 Tweety homolog 3 Large conductance chloride channel;
potential role in Ca signaling
Mm.28947
Cytoskeletal
D Dal1 Erythrocyte protein band 4.1-like 3 Actin binding protein; unknown
biological function
Mm.132761
u Mapt Microtubule-associated protein tau Microtubule-associated protein enriched
in axons; unknown biological function
Mm.1287
Kinase
D Acp6 Acid phosphatase 6, lysophosphatidic Acid phosphatase; unknown biological function Mm.101368
D Clk4 CDC like kinase 4 Kinase; potential involvement in the ubiquitination
pathway
Mm.239354
D Etnk1 Ethanolamine kinase 1 Ethanolamine kinase; unknown biological function Mm.272548
U c Yes Yamaguchi sarcoma viral
(v-yes) oncogene homolog
Src kinase family member; unknown
biological function
Mm.4558
Metabolism and biosynthesis
Db Cdo1 Cysteine dioxygenase 1, cytosolic Dioxygenase involved in taurine biosynthesis Mm.241056
D Cryl1 Crystalline, lambda 1 Oxoreductase; unknown biological function Mm.25539
d Iars2 Isoleucine-tRNA synthetase 2, mitochondrial tRNA aminoacylation
D Lyzs Lysozyme Catabolic enzyme; unknown biological function Mm.45436
D Nudt11 Nudix (nucleoside diphosphate linked moiety X)-
type motif 11
Phosphohydrolase; unknown biological significance Mm.41198
Da Ogt O-linked N-acetylglucosamine
(GlcNAc) transferase
Transcriptional repressor complex component;
immune function
Mm.259191
D Prss35 Protease, serine, 35 Protease; unknown biological function Mm.257629
D Wfdc1 WAP four-disulfide core domain 1 Endopeptidase; unknown biological activity Mm.87599
u Bak1 BCL2 antagonist/killer 1 Activator of caspases and involved in
apoptosis
Mm.2443
ua Cox15 COX15 homolog, cytochrome c oxidase
assembly protein
Oxidative metabolism; ATP synthesis Mm.248237
Ub Ddc Dopa decarboxylase Catecholamine metabolism Mm.12906
U Hibch 3-Hydroxyisobutyryl-coenzyme A hydrolase Hydrolase; unknown biological function Mm.222063
ua Trnt1 tRNA nucleotidyl transferase, CCA-adding, 1 tRNA nucleotidyltransferase; unknown
biological function
Mm.196332
Metabolite transport
D Copg2 Coatomer protein complex, subunit gamma 2 Protein transporter complex;
unknown biological function
Mm.335639
D Stx17 Syntaxin 17 Unknown biological function Mm.171334
D Stx8 Syntaxin 8 Vesicular trafficking and docking Mm.39095
U Cubn Cubilin (intrinsic factor-cobalamin receptor) Receptor involved in endocytosis Mm.313915
(continued on next page)
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Table 2 (continued)
Up/downA Gene symbol Gene title Proposed biological functions Unigene code
Metabolite transport
ua Hsdl2 Hydroxysteroid dehydrogenase like 2 (Hsdl2) Sterol carrier activity; unknown biological activity Mm.272905
U Usp13 Ubiquitin-specific protease 13 Small ubiquitin-related modifier-mediated nuclear
import
Mm.316153
Signal transduction
Db Cxxc4 CXXC finger 4; Idax Negative regulator of Wnt signaling Mm.224814
Db, d Dkk3 Dickkopf homolog 3 (Xenopus laevis) Secreted inhibitor of Wnt signaling Mm.55143
Db Fbxo32 F-box only protein 32 Ubiquitin ligase; inhibitor of
calcineurin-induced hypertrophy
Mm.292042
D Gnb4 Guanine nucleotide binding protein, beta 4 G-protein coupled receptor; unknown biological function Mm.139192
d Gsk3b Glycogen synthase kinase 3 beta Signaling molecule in the Wnt/beta-catenin pathway Mm.200770
d Hhat Hedgehog acetyltransferase Palmitoylation of Drosophila Hh needed for secretion;
Hedgehog signaling pathway
Mm.145857
d Igfbp5 Insulin-like growth factor binding protein 5 Insulin-like growth factor regulation of cell growth;
binds specifically with Fhl2, also downregulated
Mm.309617
da Lnk Linker of T-cell receptor pathways Adaptor protein modulating hematopoietic
progenitor cell differentiation
Mm.65493
d Lnx1 Ligand of numb-protein X 1 Putatively involved in neuregulin-1/ErbB signaling
D Plcd1 Phospholipase C, delta 1 PKC signaling molecule involved in ischemic
heart response
Mm.23963
dd,d Slit2 Slit homolog 2 Secreted negative regulator of axonal extension Mm.289739
Db Vsnl1 Visinin-like 1 Calcium binding protein; unknown biological function Mm.27005
D Wisp1 WNT1 inducible signaling pathway protein 1 Wnt signaling pathway; potential growth factor Mm.10222
u Bsf3 Cardiotrophin-like cytokine factor 1 Cytokine involved in Jak/STAT signaling Mm.347919
u Oprl1 Kappa3-related opioid receptor isoform E G-protein coupled receptor Mm.285075
u Tslpr Thymic stromal-derived lymphopoietin,
receptor
Cytokine receptor Mm.35771
Transcription and transcriptional regulation
Db Brd8 Bromodomain containing 8 Transcription factor; nuclear coactivator of aRxr Mm.45602
D Ddit3 DNA damage-inducible transcript 3 Transcription factor involved in stress-mediated
apoptosis
Mm.110220
D Eya1 Eyes absent 1 homolog (Drosophila) Transcription factor; implicated in Caylor
cardiofacial syndrome
Mm.250185
Db,d Hand1 Heart and neural crest derivatives
expressed transcript 1
Transcription factor/expressed in left ventricle Mm.4746
da Hcfc1 Host cell factor C1 Transcriptional coregulator; part of HDAC DNA
methylation/demethylation complex
Mm.248353
d Hrmt1l1 Heterogeneous nuclear ribonucleoprotein
methyltransferase-like 1
S-adenosylmethionine-dependent
methyltransferase activity;
may be involved in regulation of transcription
Mm.32020
Db,d Irx2 Iroquois-related homeobox 2 (Drosophila) Transcription factor/expressed in IVS Mm.28888
D LOC433393 Weakly similar to diaphanous protein
homolog 1
Putative TATA-box binding protein;
unknown biological function
Mm.331444
Da Nolz1 Zinc finger protein 503 Putative transcription factor Mm.292401
D Rbed1 RNA binding motif and ELMO domain 1 Nucleic acid binding protein; unknown biological function Mm.24440l
Db,d Shox2 Short stature homeobox 2 Transcription factor/expressed in developing vena cava Mm.39093
Db Tbx3 T-box transcription factor 3 Transcription factor/expressed in developing
conduction system
Mm.87711
D Tia1 Cytotoxic granule-associated RNA
binding protein 1
Translational silencer; RNA-binding protein Mm.274425
da,b Yap1 Yes-associated protein WW domain containing transcriptional coactivator Mm.221992
Ua Ddx52 DEAD (Asp-Glu-Ala-Asp) box
polypeptide 52
Putative helicase activity Mm.280544
u HoxB7 Homeobox B7 Hox-cluster transcription factor Mm.4822
Known genes and ESTs with unknown function
d 1110033J19 RIKEN cDNA 1110033J19 gene Unknown biological function Mm.3572
Da 1300012G16 RIKEN cDNA 1300012G16 gene Unknown biological function Mm.100065
D 1810015C04 RIKEN cDNA 1810015C04 gene Unknown biological function Mm.25311
D 2210403K04 RIKEN cDNA 2210403K04 gene Unknown biological function Mm.41393
D 2610024A01 RIKEN cDNA 2610024A01 gene Unknown biological function Mm.281287
d 2610318I15 RIKEN cDNA 2610318I15 gene Unknown biological function Mm.262707
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Table 2 (continued)
Up/downA Gene symbol Gene title Proposed biological functions Unigene code
Known genes and ESTs with unknown function
D 4921517N04 Riken cDNA 4921517N04 gene Unknown biological function Mm.276415
D 4933417N17 Hypothetical protein 4933417N17 Unknown biological function Mm.72979
Da 4933428I03 RIKEN cDNA 4933428I03 gene Unknown biological function Mm.254605
D 5730508B09 RIKEN cDNA 5730508B09 gene Unknown biological function Mm.317049
d BC031781 cDNA sequence BC031781 Unknown biological function Mm.272625
D C230093N12 RIKEN cDNA C230093N12 gene Unknown biological function Mm.4065
D Copg2as2 Coatomer protein complex,
subunit gamma 2, antisense 2
Antisense of the imprinted gene Copg2;
Unknown biological function
Mm.22891
D D12Ertd553e D12Ertd553e Unknown biological function Mm.275699
D E130311K13 Hypothetical protein E130311K13 Unknown biological function Mm.39342
D LOC432731 Similar to zinc finger protein 187 Unknown biological function Mm.235360
D mKIAA1961 mKIAA1961 protein Unknown biological function Mm.34087
d Mtcp1 Mature T-cell proliferation 1 Gene expressed in T-cell leukemias;
Unknown biological function
Mm.16366
d Trim5 Tripartite motif protein 5 Unknown biological function Mm.259010
u 0610009K11 RIKEN cDNA 0610009K11 gene Unknown biological function Mm.103413
U 2010308M01 RIKEN cDNA 2010308M01 gene Unknown biological function Mm.371646
ua 2810487N22 RIKEN cDNA 2810487N22 gene Unknown biological function
U 4122402O22 RIKEN cDNA 4122402O22 gene Unknown biological function Mm.34659
U 4930429A08 RIKEN cDNA 4930429A08 gene Unknown biological function Mm.172064
u 4930461P20 RIKEN cDNA 4930461P20 gene Unknown biological function Mm.297862
U A230046K03 RIKEN cDNA A230046K03 gene Unknown biological function Mm.278577
ua AI413631 cDNA sequence AI413631 Unknown biological function Mm.310434
ua Bola3 bolA-like 3 Unknown biological function Mm.52024
Ua Chchd6 Coiled-coil-helix-coiled-coil-helix
domain containing 6
Unknown biological function Mm.20313
U Pqlc3 PQ loop repeat containing 3 Unknown biological function Mm.5675
u Stom Stomatin Unknown biological function Mm.295284
U Trim47 Tripartite motif protein 47 Unknown biological function Mm.5510
u Trim62 Tripartite motif-containing 62 Unknown biological function Mm.30653
U/D, significantly upregulated or downregulated, respectively, with expression change log2 > ±0.3. u/d, significantly upregulated or downregulated respectively with
expression change log2 < ±0.3. Note that upregulation or downregulation of gene expression was based on Tbx5del/+ relative to WT.
a Conflicting direction of expression changes between Tbx5lox/+ and Tbx5del/+ data (i.e., expression significantly down in Tbx5lox/+ but significantly up in
Tbx5 del/+ or visa versa, perhaps due to secondary compensatory responses).
b Confirmed by either in situ hybridization or real-time PCR as having a significant expression change consistent with the microarray data.
c In situ hybridization or real-time PCR was not able to confirm a significant expression change as reported in the array.
d P values (del/+ vs. WT) between 5% and 10%.
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(Fig. 7A; Supplemental Figure 2). Additionally, we also
quantitated expression of the transcription factors Hand1,
Shox2, Irx2, and Irx1—expressed in an overlapping domain
with Irx2 in the intraventricular septum (Christoffels et al.,
2000) and found all were significantly decreased in Tbx5del/+
and Tbx5lox/+ hearts. Tbx2, expressed in an overlapping pattern
with Tbx3 in the atrioventricular canal (Gibson-Brown et al.,
1998; Habets et al., 2002; Yamada et al., 2000), was not
increased in mutant hearts (Supplemental Figure 2). Expression
ofMyl2 and Irx4 (genes known to be downregulated exclusively
in Tbx5del/del embryos) were used as negative controls and
showed no statistically significant changes in expression in
either heterozygous mutant. In total, we independently
confirmed expression changes in 17 of 23 genes (74%)
consistent with the changes reported by the microarray screen.
When changes in gene expression (δx) were examined as a
function of Tbx5 mRNA levels (δd), several different
expression kinetics were observed, most likely indicative of
varying modes of gene regulation (Figs. 7B–J). At one extreme,
δx/δd for Gja5 expression remained constant at all Tbx5 levelsexamined (R2 = 0.77), as reflected by the linear relationship
between Tbx5 dosage and Gja5 expression. In comparison, the
δx/δd of Vsnl1, Shox2, and Ddc was constant at concentrations
of Tbx5 near 100% but rapidly changed at lower Tbx5 dosages,
consistent with a prompt loss in either gene activation (Vsnl1,
Shox2) or in gene repression (Ddc). Tbx3 exhibited the most
dynamic changes in expression, best described by a sinusoidal
curve (R2 = 0.73) such that the δx/δd was constant at high and
low concentrations of Tbx5 but changed rapidly between 50%
and 90% WT Tbx5 mRNA levels, consistent with a threshold-
mediated method of gene expression control. Examination of
Irx4 (Fig. 5G; R2 = 0.007) or Myl2 (R2 = 0.003) expression
showed no obvious change in the general level of expression of
with decreasing Tbx5 dosage within the range of Tbx5 mRNA
levels examined (δx/δd ≈ 0).
Of the 16 genes examined in Tbx5lox/+, 6 showed greater
expression changes in hypomorphic samples than in Tbx5del/+
hearts, albeit in only one case (Brd8) was this difference
statistically significant (P < 0.0001). By plotting the expression
of these genes, more complex interactions were observed. For
instance, Brd8 expression was increased in Tbx5del/+ hearts
Table 3
Moderately sensitive Tbx5 downstream genes (only altered in Tbx5del/+)
Up/downA Gene symbol Gene title Proposed biological functions Unigene code
Cell cycle
u Orc1l Origin recognition complex, subunit 1-like Involved in DNA replication initiation Mm.294154
U S100a6 S100 calcium binding protein A6 (calcyclin) Cation sensing protein involved in cell
cycle regulation
Mm.100144
Channel Forming
U Kctd10 Potassium channel tetramerization domain
containing 10
Ion channel; unknown biological function Mm.268504
u Nupl1 Nucleoporin like 1 Nuclear pore complex Mm.258051
Cellular/structural component
d Myl7 Myosin, light polypeptide 7, regulatory Cytoskeletal component Mm.46514
D Nup214 Nucleoporin 214 Part of nuclear pore complex Mm.127697
d Phlda1 Pleckstrin homology-like domain, family A,
member 1
FasL-mediated induction of apoptosis Mm.3117
d Rpl28 Ribosomal protein L28 Ribosomal structural protein Mm.379002
d Rpl4 Ribosomal protein L4 Ribosomal structural protein Mm.280083
d Tspan5 Tetraspanin 5 Transmembrane protein; unknown biological
function
Mm.31927
U Tnni2 Troponin I, skeletal, fast 2 Calcium transporter involved in muscle contraction Mm.39469
Kinase
d Cerk Ceramide kinase Ceramide phosphorylation; mediator of
apoptosis pathway
Mm.222685
D Hk1 Hexokinase 1 Hexokinase; unknown biological function Mm.213213
D Prkab1 Protein kinase, AMP-activated,
beta 1 non-catalytic subunit
AMP-activated protein kinase;
unknown biological function
Mm.200912
U Ltb4dh Leukotriene B4 12-hydroxydehydrogenase Alcohol dehydrogenase; unknown biological
function
Mm.34497
u Prkar2b Protein kinase, cAMP-dependent regulatory,
type II beta
Regulatory subunit of cAMP-kinases Mm.25594
U Riok2 RIO kinase 2 Kinase; unknown biological function Mm.218423
Metabolism and biosynthesis
d Asph Aspartate-beta-hydroxylase Peptide-aspartate beta-dioxygenase activity;
unknown biological activity
Mm.239247
d Entpd5 Ectonucleoside triphosphate diphosphohydrolase 5 Extracellular NTP-ase activity;
unknown biological activity
Mm.10211
d Ercc1 Excision repair cross-complementing rodent repair
deficiency, complementation group 1
DNA damage repair Mm.280913
D Lap3 Leucine aminopeptidase 3 Aminopeptidase; unknown biological function Mm.341797
d Lrrc41 Leucine-rich repeat containing 41 Ubiquitin ligase Mm.260786
d Nudt13 Nudix (nucleoside diphosphate linked moiety X)-
type motif 13
Hydrolase activity; unknown biological activity Mm.317636
D Sulf2 Sulfatase 2 Sulfuric ester hydrolase; unknown biological function Mm.280459
u Adss2 Adenylosuccinate synthetase 2, non-muscle Adenylosuccinate synthase activity;
unknown biological activity
Mm.338021
u Agpat3 1-Acylglycerol-3-phosphate O-acyltransferase 3 Acyltransferase activity; phospholipid biosynthesis Mm.141230
U Bdh 3-Hydroxybutyrate dehydrogenase
(heart, mitochondrial)
Oxidoreductase; unknown function Mm.293470
U Gpt2 Glutamic pyruvate transaminase
(alanine aminotransferase) 2
Transaminase; unknown biological function Mm.200423
u Rad51c Rad51 homolog c DNA damage repair Mm.37376
U Spi6 Serine (or cysteine) proteinase inhibitor,
clade B, member 9
Peptidase involved in immune response Mm.3368
Metabolite transport
d Cpne5 Copine V Calcium-dependent phospholipid-binding protein;
putative molecular chaperone
Mm.39905
d Dnajb12 DnaJ (Hsp40) homolog, subfamily B, member 12 Molecular chaperone Mm.103610
D Doc2g Double C2, gamma Vesicular transport Mm.266972
d Kpnb3 Karyopherin (importin) beta 3 Nuclear import protein Mm.221452
u Kpna3 Karyopherin (importin) alpha 3 Nuclear import protein Mm.25548
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Table 3 (continued)
Up/downA Gene symbol Gene title Proposed biological functions Unigene code
Signal transduction
D Braf Braf transforming gene Protein involved in extracellular signal-regulated
kinase (ERK) signaling
Mm.245513
d Capn6 Calpain 6 Calcium-dependent cysteine protease; unknown
biological function
Mm.30290
D Gnb3 Guanine nucleotide binding protein, beta 3 G-protein-coupled receptor; unknown biological function Mm.68889
D Pak2 P21 (CDKN1A)-activated kinase Role in non-Smad Tgf-beta signaling Mm.234204
d Sema4d Semaphorin 4D Secreted negative regulator of axonal extension Mm.33903
u Arl6 ADP ribosylation factor-like 6 GTPase signal transduction Mm.7760
U Sema6a Semaphorin 6A Transmembrane negative regulator of axonal extension Mm.40909
Transcription and transcriptional regulation
d Ascc1 Activating signal cointegrator 1 complex subunit 1 Transcriptional coactivator Mm.155839
D a Cited1 Cbp/p300-interacting transactivator
with Glu/Asp-rich carboxy-terminal domain 1
Transcription factor/expressed dynamically in the heart Mm.2390
D E4f1 E4F transcription factor 1 Transcription factor which is also needed for mitosis Mm.163132
D Eif4g1 Eukaryotic translation initiation factor 4, gamma 1 Transcription initiation factor Mm.260256
d Fhl2 Four and a half LIM domains 2 Muscle-restricted transcriptional coactivator;
expressed in heart
Mm.6799
d Foxk2 Forkhead box K2 Transcription factor; unknown biological function Mm.209750
D Gli2 GLI-Kruppel family member GLI2 Transcription factor; Shh signal transduction Mm.273292
d Thoc2 THO complex 2 Transcriptional elongation and mRNA export factor Mm.259498
d b Taz WW domain containing transcription regulator 1 (W) domain containing positive transcriptional
coregulator; expressed in the heart
Mm.227202
d Zbtb9 Zinc finger and BTB domain containing 9 Transcription factor; unknown biological function Mm.328890
D Zfp207 zinc finger protein 207 Transcription factor Mm.102253
U Ddx54 DEAD (Asp-Glu-Ala-Asp) box polypeptide 54 Putative transcription factor; helicase activity Mm.62044
U Hmgb1 High mobility group box 1 DNA-binding protein; potential cytokine Mm.207047
Ua Syncrip Synaptotagmin binding, cytoplasmic RNA
interacting protein
mRNA stabilization Mm.260545
Known genes and ESTs with unknown function
D 0610037L13 RIKEN cDNA 0610037L13 gene Unknown biological function Mm.274853
D 1498131 Mus musculus, clone IMAGE:1498131, mRNA Unknown biological function Mm.374459
d 1810007M14 RIKEN cDNA 1810007M14 gene Unknown biological function Mm.347
d 2310009B15 RIKEN cDNA 2310009B15 gene Unknown biological function Mm.264673
d 2410029D17 RIKEN cDNA 2410029D17 gene Unknown biological function N/A
d 2610204M12 RIKEN cDNA 2610204M12 gene Unknown biological function Mm.361788
D 4833427F10 RIKEN cDNA 4833427F10 gene Unknown biological function Mm.290828
D 4930565B19 RIKEN cDNA 4930565B19 gene Unknown biological function Mm.28804
d 4933439C20 RIKEN cDNA 4933439C20 gene Unknown biological function Mm.335641
d 6430550H21 RIKEN cDNA 6430550H21 gene Unknown biological function Mm.383286
d Adprhl2 ADP ribosylhydrolase like 2 Unknown biological function Mm.11285
D BC031361 cDNA sequence BC031361 Unknown biological function Mm.359954
D C130052G03 RIKEN cDNA C130052G03 gene Unknown biological function Mm.276075
d Mest Molossinus mesoderm-specific transcript Unknown biological function Mm.335639
d MGC38812 Hypothetical protein MGC38812 Unknown biological function Mm.206371
d Pqlc1 PQ loop repeat containing 1 Unknown biological activity Mm.29247
u 0610010O12 RIKEN cDNA 0610010O12 gene Unknown biological function Mm.272527
u 1700027J05 RIKEN cDNA 1700027J05 gene Unknown biological function Mm.383229
U 3632431M01 Transmembrane and coiled coil domains 1 Unknown biological function Mm.333338
U 4921529O18 RIKEN cDNA 4921529O18 gene Unknown biological function Mm.266280
u AV214133 cDNA sequence AV214133 Unknown biological function
U BC023488 cDNA sequence BC023488 Unknown biological function Mm.209490
u BI134269 cDNA sequence BI134269 Unknown biological function Mm.339029
U C330027C09 RIKEN cDNA C330027C09 gene Unknown biological function Mm.24491
u Rga Recombination activating gene 1 gene activation Unknown biological function; membrane protein Mm.17958
u Tmepai Transmembrane, prostate androgen-induced RNA Unknown biological function; membrane protein Mm.73682
U/D, significantly upregulated or downregulated respectively with expression change log2 > ±0.3. u/d, significantly upregulated or downregulated respectively with
expression change log2 < ±0.3. Note that upregulation or downregulation of gene expression was based on Tbx5del/+ relative to WT.
a In situ hybridization or real-time PCR was not able to confirm a significant expression change as reported in the array.
b Confirmed by either in situ hybridization or real-time PCR as having a significant expression change consistent with the microarray data.
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Fig. 6. Whole-mount and section in situ hybridization (performed at E10.5 and E11.5, respectively) examining expression of 8 genes identified on the microarray
revealing significant changes in expression consistent with microarray data. Agpat3 (A, A′), Hand1 (B–B″), Slit2 (C–C″), Dkk3 (D, D′, G, G′ H, H″), Hk1 (E–E″),
Wisp1 (F–F″), Fbxo32 (I, I′, J, J′) and Tbx3 (K, K′, L, L′) all show downregulation by in situ. In addition,Wisp1 expression is expanded through the interventricular
septum (see * in F′ and F″). Squares in panels G–L show those regions that are magnified in panels G′–L′).
580 A.D. Mori et al. / Developmental Biology 297 (2006) 566–586while it was decreased in Tbx5lox/+ hearts leading to an inverted
bell-shaped curve. In contrast, Cdo1 expression could not be
described by a trend line but rather appeared to separate into two
distinct clusters, one higher than another. Cardiac expression of
Fbxo32 showed a clearly linear relationship in wild-type and
Tbx5lox/+ samples and in a subset of Tbx5del/+ hearts. However,Fig. 7. Quantitative real-time PCR analysis of gene expression. (A) Average change
hearts by microarray analysis; *P < 0.05. Irx4 andMyl2 are negative controls. (B–J)
reveal different kinetic interactions from linear (Gja5) to sinusoidal (Tbx3). The exp
within individual hearts of the same genotype, suggesting that compensatory mecha
Tbx5. 100% is defined as the average of wild type on both axes.at the lower extreme, some heterozygous null hearts begin
expressing more Fbxo32.
An important caveat of these analyses is that difference in
gene expression measured from whole E12.5 hearts may not
reflect dynamic spatiotemporal changes in gene expression,
such as the decreased but expanded expression of Nppa, ands in gene expression of 16 genes shown to have altered expression in Tbx5del/+
Profiles of gene expression in individual hearts in relation to Tbx5 mRNA levels
ression of genes such as Cdo1 and Fbxo32 appear to be differentially expressed
nisms might be adjusting gene expression to try and compensate for the loss of
581A.D. Mori et al. / Developmental Biology 297 (2006) 566–586furthermore, changes in distinct regions of the heart might be
masked by the absence of change elsewhere in the heart. It is
also possible that the differential expression of some genes maybe reflective of decreased growth or failed differentiation of
certain cardiac structures, which cannot be assessed by
measuring gene expression. Therefore, these 182 gene clusters
582 A.D. Mori et al. / Developmental Biology 297 (2006) 566–586do not represent an exhaustive list of Tbx5-regulated genes but
rather are a subset of Tbx5 dosage-sensitive genes, some of
which may be causative in the etiology of HOS. Nonetheless, it
is clear that dosage of Tbx5 is key to regulation of several genes
in complex and dynamic patterns.Fig. 8. Frequency and positioning of T-box and Nkx2.5 transcription factor binding si
for T-box binding sites (TBEs) and Nkx2.5 binding sites (NBEs) were used to define
clustered sites tends to increase in the genomic region surrounding Tbx5 dosage-sen
NKE clusters on DNA surrounding both Tbx5-sensitive genes (C), and Tbx5-ins
downstream and within intronic regions, suggesting that TBE position by itself is n
mouse and dog (α), mouse and human (β), and mouse and rat (δ).Tbx5 binding site clusters in dosage-sensitive genes
Tbx5 binds a consensus DNA sequence loosely defined as
A/G/TG/AGTGNNA. Using a position weight matrix (PWM)
based on all published T-box binding sites (Fig. 8A), an in silicotes surrounding Tbx5-sensitive genes. (A) High-quality position weight matrices
transcription factor binding sites. (B) The frequency of TBEs either alone or as
sitive targets (±standard error). (C–E) Genomic positioning of TBEs and TBE/
ensitive (D) and Tbx5-independent genes (E) appear dispersed both up- and
ot predictive of Tbx5 dosage sensitivity. Alignments were performed between
583A.D. Mori et al. / Developmental Biology 297 (2006) 566–586analysis of potential genomic regulatory regions, both around
and within the validated set of Tbx5 dosage-sensitive genes, was
performed using MULAN and MultiTF to examine the
frequency and position of evolutionarily conserved T-box
binding elements (TBEs) between mouse, human, rat, and
dog. In addition, as synergy with Nkx2-5 may be a key
mechanism for dosage sensitivity, a similar analysis was
performed to identify Nkx2.5 binding sites (NBEs) using the
PWM shown in Fig. 8A. A set of 9 myocardial genes insensitive
to Tbx5 dosage (defined as not altered on the Tbx5del/+
microarray) were used as a control set to determine the baseline
frequency of randomly positioned TBEs/NBEs within a given
genomic region.
The positioning of lone TBEs or TBE/NBE clusters within
the DNA surrounding dosage-sensitive targets reveals no
obvious spatial similarities between genes (Fig. 8C). Transcrip-
tion factor binding sites surrounding Tbx3, as an example, are
located exclusively upstream of the gene and consist of
numerous TBEs and two clustered sites separated by greater
than 15kb. In contrast, DNA binding sites near Irx2 are almost
exclusively located within the 3′ UTR and downstream
genomic region where several clustered sites appear to be
tightly grouped. Irx1 and Hand1, in comparison, have both up-
and downstream clustered sites, whereas Shox2 has numerous
dispersed sites within intronic DNA. Similarly, when transcrip-
tion factor binding sites were examined in the set of Tbx5-
insensitive/independent genes (Figs. 8D and E), no obvious
pattern in binding site position was noted, although the number
of sites (both lone and clustered sites) did seem to decrease (see
below). This analysis suggests that the positional location of
TBEs and NBEs is not predictive of a gene's sensitivity to Tbx5
dosage. It should be noted, however, that this search is not
exhaustive of all possible Tbx5 interactions (Tbx5 has been
shown to physically interact and synergize with GATA4 for
example; Garg et al., 2003) and is limited to the examination of
only 25kb upstream and 15kb downstream surrounding the
genes of interest.
The number of TBEs and clustered TBE/NKE sites were
quantitated in both our highly sensitive (n = 17) and non-
sensitive (n = 9) group of genes (Fig. 8B). Keeping in mind
that it is unlikely that all 17 analyzed Tbx5-sensitive genes are
direct Tbx5 targets, our analysis reveals that Tbx5-sensitive
genes have a trend towards having greater numbers of TBEs
within the genomic region flanking them than genes in the
non-sensitive control group (7.4 ± 3.4 vs. 2.4 ± 0.5). In
addition, the number of clustered TBE/TBE and TBE/NKE
sites also tends to be higher in the sensitive population
(1.0 ± 0.7SE vs. 0.1 ± 0.1SE and 2.2 ± 1.0SE vs.0.3 ± 0.2SE,
respectively). Therefore, increased TBE density, either alone
or in close association with Nkx2.5 sites, may be a potential
indicator of Tbx5 dosage sensitivity.
Discussion
We have shown, using a Tbx5 allelic series, that the
developing mouse heart is exquisitely sensitive to altered
dosage of Tbx5 (summarized in Table 1). By geneexpression profiling, we have uncovered subsets of genes
downstream of Tbx5 that may be involved in regulating
CHD severity due to Tbx5 haploinsufficiency. The rheostatic
regulation of cardiac gene expression by Tbx5 indicates that
the variable expressivity of TBX5 mutations in humans is
likely to be due to threshold regulation of differentially
sensitive genes.
Tbx5 dosage and cardiac morphogenesis
We observed a very close correlation between Tbx5 dosage
and the severity of defective cardiac morphogenesis. Hypo-
morphic heterozygous mice (Tbx5lox/+) consistently had milder
conduction system disease and a concurrent dramatic increase
in survivability over the heterozygous null mice. Likewise,
homozygous hypomorphs (Tbx5lox/lox) had better developed
cardiac structures and survived one day longer than Tbx5del/del
null embryos. These results illustrate that even slight differences
in Tbx5 dosage (of <15%) during development can lead to
dramatic changes in phenotype.
In examining the differences observed between Tbx5
hypomorphic and null mutants, we observed a large initial
disparity in Tbx5 dosage between heterozygous mutants.
Interestingly, this difference was observed at E8.5, at a time
when Tbx5 is expressed as an anterior–posterior gradient in
the linear heart tube with strongest expression in posterior
regions destined to become atria (Bruneau et al., 1999).
Furthermore, it has been suggested that Tbx5 might bind its
own promoter and induce its own expression in vitro (Sun
et al., 2004). If Tbx5 does regulate its own expression in
vivo, small differences in initial Tbx5 dosage due to
haploinsufficiency may result in delayed establishment of
this anterior–posterior event, thus postponing or precluding
crucial patterning or differentiation events within the heart.
Differential sensitivity of downstream genes to the Tbx5 dosage
gradient
Increased severity of CHDs due to decreased Tbx5 levels
correlated with critical changes in gene expression, and
translated to altered survival. It is likely that genes that are
highly sensitive to perturbations in Tbx5 levels are
associated with fundamental disease-associated processes,
whereas those that are only moderately affected by Tbx5
haploinsufficiency perhaps have roles in modulating the
severity of the HOS-associated defects. In human popula-
tions, this might be reflected in the large variation that
exists in families with HOS or other CHDs. Modifier genes
might therefore be involved in modulating Tbx5 expression
from the remaining wild-type allele in response to
haploinsufficiency or may act as genetic amplifiers to
enhance expression of specific Tbx5 targets.
Dynamics of gene regulation by Tbx5
Examination of expression dynamics for genes regulated by
Tbx5 illustrates distinctly different responses to decreasing
584 A.D. Mori et al. / Developmental Biology 297 (2006) 566–586Tbx5 dosage. The expression of a subset of genes can be
defined as a direct function of the dosage of Tbx5 as would
be expected if they represent direct Tbx5 targets, as has been
shown for Gja5 (Bruneau et al., 2001). In contrast, expression
of other genes can change rapidly at lower levels of Tbx5,
and in some cases gene expression changes were observed to
exhibit stochastic expression properties. The regulatory
modules that control the Tbx5 responsiveness of the former
subset of downstream genes must be regulated by more
complex interactions between Tbx5 and other positively or
negatively acting transcription factors, whereas the latter
group appear only Tbx5 dose-responsive in a subset of the
same genotype, most likely due to the action of additional
genetic modifiers that might independently adjust gene
expression to compensate for the loss of Tbx5. Deciphering
the nature of these dynamic transcriptional rheostats in model
organisms has to date yielded conflicting information, and
thus will be difficult to resolve. Together these data indicate
that Tbx5 can regulate downstream genes via an array of
independent mechanisms, some of which will include direct
DNA binding, and others via indirect mechanisms that may
involve complex regulatory networks.
Tbx5 regulates transcription factor networks in the heart
Several of the genes identified by gene expression
profiling are transcription factors or are involved in
transcriptional regulation, which places Tbx5 upstream of
numerous different transcriptional cascades in the developing
heart. For example, the transcriptional repressor Tbx3 is
significantly reduced in the Tbx5 mutant hearts. Tbx3 cardiac
expression is seen from E8.5 onward in the myocardium that
will become cardiac conduction system and is maintained
throughout development in the sinoatrial and atrioventricular
nodes as well as in the cardiac bundle branches (Hoogaars et
al., 2004). Tbx5 and Tbx3 compete for binding sites on the
promoters of Gja5 and Nppa (two direct targets activated by
Tbx5) in dosage-dependent manners (Hoogaars et al., 2004).
Our results suggest that Tbx5 normally enhances Tbx3Fig. 9. This gene regulatory network is implied by microarray and real-time data wh
Tbx3 with Nkx2.5.expression, thus creating a regulatory feedback circuit
whereby Tbx5 sustains the expression of Tbx3, which in
turn locally counters the activation of certain genes by Tbx5
within the cardiac conduction system (Fig. 9). That the
regulation of Tbx3 is sensitive to Tbx5 dosage allows for the
creation of sharp boundaries of expression upon reaching a
given dosage of Tbx5 thus ensuring the correct balance
between activator (Tbx5) and repressor (Tbx3) is maintained.
This reveals a crucial and very fine genetic interaction
between T-box transcription factors in the developing heart,
which has evolved very specifically to preserve accurate
spatiotemporal transcription of cardiac genes even in the face
of genetic disturbances. The architecture of such a genetic
feedback loop where transactivator and transrepressor com-
pete for binding to common DNA binding sites has been
shown to induce rapid dosage-dependent switching behaviour
in gene expression in vitro (Rossi et al., 2000).
The transcriptional coactivators Yap1 and Taz are also both
downregulated in Tbx5mutant mice. It has been shown recently
that both Yap1 and Taz interact as part of the Tbx5
transcriptional machinery to potently promote Tbx5-dependent
transcription (Murakami et al., 2005). It has been suggested that
this coactivation may occur through interactions between Taz
and histone acetyltransferases (HATs) (Murakami et al., 2005).
It is possible therefore that the differential sensitivity of
downstream genes to Tbx5 dosage is due in part to varying
degrees of histone modification of Tbx5 target gene promoter
sequences. Minor perturbations in the level of Tbx5, combined
with further decreases in the expression of both Taz and Yap1
would render genes in highly deacetylated regions of chromatin
less accessible to Tbx5 activation, whereas genes situated less
condensed regions of chromatin would be less sensitive to
decreased HAT recruitment and would therefore remain
transcriptionally active.
In addition to disrupting transcriptional networks, Tbx5
haploinsufficiency also alters numerous signaling cascades in
the developing heart. The secreted signaling molecule Slit2 that
we show to be predominantly expressed in ventricular
trabeculae is also downstream of Tbx5 in the heart. Slit2,erein the regulation of Gja5 and Nppa occur via interactions between Tbx5 and
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ing, has also been shown to act as a potent chemorepellant
during cell migration (Wu et al., 2001). Additionally,
Drosophila slit has recently been shown to act as a guide to
align myocardial cells converging at the midline during heart
tube closure in fly (Qian et al., 2005). The expression of Slit2 on
either side of the interventricular septum may form a repulsive
corridor that might help position the location of septal
outgrowth.
Tbx5 mutant mice also show disruptions in the expression of
genes involved in inhibition of the Wnt/β-catenin signaling
pathway (Cxxc4, Dkk3). The balance between Wnts and their
antagonists play a critical role in shaping the primary heart field
during early cardiogenesis. Wnt/β-catenin signals emanating
from the neural tube act as negative regulators of myocardial
cell fate (Marvin et al., 2001; Tzahor and Lassar, 2001). Wnt
antagonists counterbalance these inhibitory signals and have
been shown to play important roles in promoting cardiac
mesoderm formation (Lickert et al., 2002; Marvin et al., 2001;
Tzahor and Lassar, 2001). Decreases in Cxxc4 and Dkk3 in
Tbx5-deficient mice most likely would disrupt proper cell fate
specification during heart development. Decreases in Gsk3β
(involved in the Wnt-induced production of β-catenin) may
partially compensate for loss of these important Wnt inhibitors
while accounting for downregulation of Wisp1 (normally
induced by Wnt1/β-catenin expression; Xu et al., 2000).
Expanded Wisp1 expression across the interventricular septum
is also consistent with disrupted cellular specification.
T-box genes have been shown in vivo to interact in
regulatory networks to carefully pattern specific tissues through
synergistic and antagonistic interactions with other transcription
factors (including but not restricted to other T-box transcription
factors) in fish, worm, and mice (Goering et al., 2003; Koshiba-
Takeuchi et al., 2006; Pocock et al., 2004; Takeuchi et al.,
2005). Such regulatory networks of transcription factors ensure
specificity of patterning and very fine regulation of output levels
but also open up a large network to perturbed levels of the
primary regulator, in this case Tbx5.
Conclusions
The dosage of Tbx5 communicates spatiotemporal informa-
tion to cells within the early heart that is used to carefully
orchestrate patterns of cardiac development and it is well
established that decreases in Tbx5 dosage cause congenital heart
defects. We have shown that there is a direct relationship
between Tbx5 dosage during early heart development and the
severity of concomitant heart defects. It is likely that such
differences in Tbx5 dosage brought about due to slightly
different genetic backgrounds and the effect of modifier genes
account for the large variation in severity of HOS clinical
presentation. Changes in the severity of CHDs are underpinned
by differential sensitivities of downstream genes to varying
levels of Tbx5. These differences represent variation in the
underlying control elements that regulate the expression of
these genes and are important to investigate as changes in these
genes lead to a marked increase in survivability.Acknowledgments
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